| November 2012 · Vol. 24, No. 11
UPDATE ON OSTEOPOROSIS
What we’ve learned about when to measure BMD and how to identify lesser-known causes of bone loss, as well as the value of quantitative ultrasound in determining the risk of fracture. And in the pipeline: a drug that curbs bone resorption without limiting bone formation.
Steven R. Goldstein, MDDr. Goldstein is Professor of Obstetrics and Gynecology at New York University School of Medicine. He is also Director of Gynecologic Ultrasound and Co-Director of Bone Densitometry at New York University Medical Center in New York City. He serves on the OBG Management Board of Editors.
Dr. Goldstein reports that he is a consultant to Cook ObGyn and Phillips Ultrasound; a speaker for Merck and Warner Chilcott; and is on the Gyn Advisory Boards of Bayer, Depomed, Novo Nordisk, and Shionogi. He serves on the OBG Management Board of Editors.
Osteoporosis is a significant health issue—and it is likely to remain so as more and more women live longer and longer. In fact, increasing age is the single biggest risk factor for osteoporotic fragility fracture. CLICK HERE to read more |
